PhD Lenka Besse
Medizinische Onkologie und Hämatologie · Dept. I
Genetic contributors of multiple myeloma cells involved in their homing and escape from T-cell recognition
Jul 1, 2022Finding highly active treatment for patients with relapsed/refractory multiple myeloma is an unmet clinical need. The immune-based treatment approaches in this population of patients have shown notable anti-myeloma activity, with deeper and durable r...
Fundamental Research - Jul 1, 2022 - Jun 30, 2023
Automatically Closed
Project leader: Besse Lenka
Members: Besse Andrej
ALK-Inhibitoren als potentielle Therapie bei Proteasom-Inhibitor-resistentem Multiplen Myelom
Oct 1, 2021
Fundamental Research - Oct 1, 2021 - Sep 30, 2023
Automatically Closed
Project leader: Driessen Christoph
Members: Besse Lenka, Besse Andrej, Kraus Marianne
Immunoproteasome activity as a predictive marker and therapeutic target in hematological malignancies
Jul 1, 2021
Fundamental Research - Jul 1, 2021 - Dec 31, 2021
Automatically Closed
Project leader: Besse Andrej
Members: Kraus Marianne, Besse Lenka
Towards identification of novel therapeutic targets: Assessment of proteasome-related alterations in MM patients’ datasets
Jan 1, 2021
Fundamental Research - Jan 1, 2021 - Dec 31, 2021
Automatically Closed
Project leader: Besse Lenka, Buljan Marija
Members: Besse Andrej
The molecular landscape of proteasome inhibitor resistance of multiple myeloma in vivo
Jul 1, 2020We here aim to dissect the molecular landscape of MM that is acquiring resistance to the most active PI, carfilzomib (CFZ) in vivo. We therefore here extend our model to orthotopic growth conditions of MM in murine bone marrow under continuous select...
Fundamental Research - Jul 1, 2020 - Dec 31, 2023
Ongoing
Project leader: Driessen Christoph
Members: Besse Andrej, Schwestermann Jonas, Kraus Marianne, Besse Lenka
Revealing molecular basis of cardiotoxicity of carfilzomib towards its safer use in the patients with multiple myeloma
Mar 1, 2020
Fundamental Research - Mar 1, 2020 - Feb 28, 2021
Automatically Closed
Project leader: Besse Lenka
Members: Mendez-Lopez Max
The „seed and soil“-based pathogenesis of proteasome inhibitor resistance in multiple myeloma
Jan 1, 2019Using the novel method of single-sell RNA sequencing, recently established by the Institute of Immunobiology at MFZ, KSSG, and our experience and knowledge about proteasome inhibitor resistance of myeloma plasma cells in vitro, we shall use the MFZ s...
Fundamental Research - Jan 1, 2019 - Dec 31, 2019
Automatically Closed
Project leader: Besse Lenka
Members: Besse Andrej, Schwestermann Jonas
Identifying and targeting the “Achilles’ heel” in proteasome inhibitor-resistant multiple myeloma
Oct 1, 2018The proposal aims at understanding the biology of proteasome inhibitor (PI)-refractory multiple myeloma (MM), in particular the specific vulnerabilities of PI-refractory MM, or so called “Achilles’ heel”, towards development of novel treatment option...
Fundamental Research - Oct 1, 2018 - Dec 31, 2021
Automatically Closed
Project leader: Driessen Christoph
Members: Besse Andrej, Kraus Marianne, Besse Lenka, Mendez-Lopez Max
Preclinical investigation of cardiotoxicity as a clinically important side effect of proteasome inhibitor-based therapy
Jul 1, 2017Carfilzomib is the recently approved second generation proteasome inhibitor for multiple myeloma therapy. Carfilzomib has superior clinical activity than the first generation drug, bortezomib, putatively due to less off-target activity and an altered...
Fundamental Research - Jul 1, 2017 - Jun 30, 2018
Automatically Closed
Project leader: Besse Lenka
Members: Mendez-Lopez Max
HIV-Proteaseinhibitoren als Basis für Krebstherapie: Verständnis des Mechanismus, Identifikation der Targets, Entwicklung wirksamerer Substanzen
Nov 1, 2016Proteasominhibitor-Resistenz ist ein wichtiger unmet clinical need beim Multiplen Myelom (MM). Die Aktivität von next generation therapy (Daratumumab, Carfilzomib, Pomalidomid) ist hier bei ca. 30 % Partialremissionen (PR). Wir haben in vitro durch...
Fundamental Research - Nov 1, 2016 - Oct 31, 2018
Automatically Closed
Project leader: Driessen Christoph
Members: Kraus Marianne, Bader Juergen, Besse Lenka, Besse Andrej
Proteasominhibitor-resistentes Multiples Myelom: Biologie und Therapieoptionen
Jan 5, 2015Proteasom-Inhibitor (PI) Resistenz ist eines der Schlüsselprobleme in der Therapie des Multiplen Myeloms (MM), der häufigsten hämatologischen Neoplasie. Wir haben in Vorarbeiten ein in vitro-Modell des PI-resistenten MM entwickelt und Biologie-basier...
Fundamental Research - Jan 5, 2015 - Dec 31, 2015
Automatically Closed
Project leader: Driessen Christoph
Members: Besse Lenka